Drug Search Results
More Filters [+]

Tetracosactide

Alternative Names: tetracosactide
Latest Update: 2024-12-19
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Alkylating Agent

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: Intravenous,Subcutaneous,Intramuscular

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | Austria | Belgium | Canada | Chile | Denmark | Egypt | France | Germany | Greece | Ireland | Italy | Korea | Lithuania | Luxembourg | Malta | Morocco | New Zealand | Norway | Peru | Poland | Portugal | Russia | Saudi Arabia | Slovenia | Spain | Sweden | Switzerland | Thailand | Turkey | United Kingdom | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tetracosactide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events